CA
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVECOVER ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


Published online before print February 20, 2008
CA Cancer J Clin 2008
doi: 10.3322/CA.2007.0010
© 2008 American Cancer Society
This Article
Right arrow Abstract Freely available
Right arrow All Versions of this Article:
CA.2007.0010v1
58/2/71    most recent
Right arrow Submit a letter to the editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jemal, A.
Right arrow Articles by Thun, M. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jemal, A.
Right arrow Articles by Thun, M. J.

Cancer Statistics, 2008

Ahmedin Jemal, DVM, PhD, Rebecca Siegel, MPH, Elizabeth Ward, PhD, Yongping Hao, PhD, Jiaquan Xu, MD*, Taylor Murray and Michael J. Thun, MD, MS

Dr. Jemal is Strategic Director, Cancer Surveillance, Department of Epidemiology and Surveillance Research, American Cancer Society, Atlanta, GA.
Ms. Siegel is Manager, Surveillance Information Services, Department of Epidemiology and Surveillance Research, American Cancer Society, Atlanta, GA.
Dr. Ward is Managing Director, Surveillance Research, Department of Epidemiology and Surveillance Research, American Cancer Society, Atlanta, GA.
Dr. Hao is Senior Epidemiologist, Surveillance Research, Department of Epidemiology and Surveillance Research, American Cancer Society, Atlanta, GA.
Dr. Xu is Epidemiologist, Mortality Statistics Branch, Division of Vital Statistics, National Center for Health Statistics, Centers for Disease Control and Prevention, Hyattsville, MD.
Mr. Murray is Manager, Surveillance Data Systems, Department of Epidemiology and Surveillance Research, American Cancer Society, Atlanta, GA.
Dr. Thun is Vice President, Department of Epidemiology and Surveillance Research, American Cancer Society, Atlanta, GA.

    ABSTRACT

Each year, the American Cancer Society estimates the number of new cancer cases and deaths expected in the United States in the current year and compiles the most recent data on cancer incidence, mortality, and survival based on incidence data from the National Cancer Institute, Centers for Disease Control and Prevention, and the North American Association of Central Cancer Registries and mortality data from the National Center for Health Statistics. Incidence and death rates are age-standardized to the 2000 US standard million population. A total of 1,437,180 new cancer cases and 565,650 deaths from cancer are projected to occur in the United States in 2008. Notable trends in cancer incidence and mortality include stabilization of incidence rates for all cancer sites combined in men from 1995 through 2004 and in women from 1999 through 2004 and a continued decrease in the cancer death rate since 1990 in men and since 1991 in women. Overall cancer death rates in 2004 compared with 1990 in men and 1991 in women decreased by 18.4% and 10.5%, respectively, resulting in the avoidance of over a half million deaths from cancer during this time interval. This report also examines cancer incidence, mortality, and survival by site, sex, race/ethnicity, education, geographic area, and calendar year, as well as the proportionate contribution of selected sites to the overall trends. Although much progress has been made in reducing mortality rates, stabilizing incidence rates, and improving survival, cancer still accounts for more deaths than heart disease in persons under age 85 years. Further progress can be accelerated by supporting new discoveries and by applying existing cancer control knowledge across all segments of the population.

    INTRODUCTION

Cancer is a major public health problem in the United States and many other parts of the world. Currently, one in 4 deaths in the United States is due to cancer. In this article, we provide an overview of cancer statistics, including updated incidence, mortality, and survival rates, and expected numbers of new cancer cases and deaths in 2008.

    MATERIALS AND METHODS

    Data Sources
Mortality data from 1930 to 2005 in the United States were obtained from the National Center for Health Statistics (NCHS).1 Incidence data for long-term trends (1975 to 2004), 5-year relative survival rates, and data on lifetime probability of developing cancer were obtained from the Surveillance, Epidemiology, and End Results (SEER) program of the National Cancer Institute, currently covering about 26% of the US population.2–5 Incidence data (1995 to 2004) for projecting new cancer cases were obtained from cancer registries that participate in the SEER program or the Centers for Disease Control and Prevention (CDC)’s National Program of Cancer Registries (NPCR) through the North American Association of Central Cancer Registries (NAACCR). State-specific incidence rates were abstracted from Cancer in North America (2000–2004) Volume One,6 based on data collected by cancer registries participating in the SEER program and NPCR. Population data were obtained from the US Census Bureau.7 Causes of death were coded and classified according to the International Classification of Diseases (ICD-8, ICD-9, and ICD-10).8–10 Cancer cases were classified according to the International Classification of Diseases for Oncology.11

    Estimated New Cancer Cases
The precise number of cancer cases diagnosed each year in the nation and in every state is unknown because complete cancer registration has not yet been achieved in some states. Furthermore, the most recent year for which incidence and mortality data are available lags 3 to 4 years behind the current year due to the time required for data collection and compilation. Estimated new cancer cases in the current year (2008) were projected using a spatio-temporal model12 based on incidence data from 1995 through 2004 from 41 states and the District of Columbia that met NAACCR’s high-quality data standard for incidence, covering about 85% of the US population. The method also considers geographic variations in socio-demographic and lifestyle factors, medical settings, and cancer screening behaviors as predictors of incidence, and accounts for expected delays in case reporting.

    Estimated Cancer Deaths
We used the state-space prediction method13 to estimate the number of cancer deaths expected to occur in the United States and in each state in the year 2008. Projections are based on underlying cause of death from death certificates as reported to the NCHS.1 This model projects the number of cancer deaths expected to occur in 2008 based on the number that occurred each year from 1969 to 2005 in the United States and in each state separately.

    Other Statistics
We provide mortality statistics for the leading causes of death as well as deaths from cancer in the year 2005. Causes of death for 2005 were coded and classified according to ICD-10.8 This report also provides updated statistics on trends in cancer incidence and mortality rates, the probability of developing cancer, and 5-year relative survival rates for selected cancer sites based on data from 1975 through 2004.3 All age-adjusted incidence and death rates are standardized to the 2000 US standard population and expressed per 100,000 population.

The long-term incidence rates and trends (1975 to 2004) are adjusted for delays in reporting where possible. Delayed reporting primarily affects the most recent 1 to 3 years of incidence data (in this case, 2002 to 2004), especially for cancers such as melanoma, leukemia, and prostate that are frequently diagnosed in outpatient settings. The National Cancer Institute has developed a method to account for expected reporting delays in SEER registries for all cancer sites combined and many specific cancer sites.14 Delay-adjusted rates provide a more accurate assessment of trends in the most recent years for which data are available.

We also provide estimates of the total number of cancer deaths avoided due to the reduction in age-standardized cancer death rates since 1991 in men and 1992 in women. We applied the age-specific cancer death rates in the peak year for the age-standardized cancer death rates (1990 for males and 1991 for females) to the corresponding age-specific populations in the subsequent years through 2004 to obtain the number of expected deaths in each calendar year if the death rates had not decreased. We then summed the difference between the number of expected and observed deaths in each age group and calendar year for men and women separately to obtain the total number of cancer deaths avoided over the 13- or 14-year interval.

    SELECTED FINDINGS

    Expected Numbers of New Cancer Cases
Table 1 presents estimates of the numbers of new cases of invasive cancer expected among men and women in the United States in 2008. The overall estimate of about 1.44 million new cases does not include carcinoma in situ of any site except urinary bladder, nor does it include basal cell and squamous cell cancers of the skin. More than 1 million cases of basal cell and squamous cell skin cancer, about 67,770 cases of breast carcinoma in situ, and 54,020 cases of in situ melanoma are expected to be newly diagnosed in 2008. The estimated numbers of new cancer cases for each state and selected cancer sites are shown in Table 2.


View this table:
[in this window]
[in a new window]

 
Table 1 Estimated New Cancer Cases and Deaths by Sex, United States, 2008*

 

View this table:
[in this window]
[in a new window]

 
TABLE 2 Age-standardized Incidence Rates for All Cancers Combined, 2000 to 2004, and Estimated New Cases* for Selected Cancers by State, United States, 2008

 
Figure 1 indicates the most common cancers expected to occur in men and women in 2008. Among men, cancers of the prostate, lung and bronchus, and colon and rectum account for about 50% of all newly diagnosed cancers. Prostate cancer alone accounts for about 25% (186,320) of incident cases in men. Based on cases diagnosed between 1996 and 2003, an estimated 91% of these new cases of prostate cancer are expected to be diagnosed at local or regional stages, for which 5-year relative survival approaches 100%.


Figure 1
View larger version (105K):
[in this window]
[in a new window]
[PowerPoint slide for Educational Purposes]
 
FIGURE 1 Ten Leading Cancer Types for the Estimated New Cancer Cases and Deaths, by Sex, United States, 2008.

*Excludes basal and squamous cell skin cancers and in situ carcinoma except urinary bladder. Estimates are rounded to the nearest 10.

 
The 3 most commonly diagnosed types of cancer among women in 2008 will be cancers of the breast, lung and bronchus, and colon and rectum, accounting for about 50% of estimated cancer cases in women. Breast cancer alone is expected to account for 26% (182,460) of all new cancer cases among women.

    Expected Number of New Cancer Deaths
Table 1 also shows the expected number of deaths from cancer projected for 2008 for men, women, and both sexes combined. It is estimated that about 565,650 Americans will die from cancer, corresponding to over 1,500 deaths per day. Cancers of the lung and bronchus, prostate, and colon and rectum in men, and cancers of the lung and bronchus, breast, and colon and rectum in women continue to be the most common fatal cancers. These 4 cancers account for half of the total cancer deaths among men and women (Figure 1). Lung cancer surpassed breast cancer as the leading cause of cancer death in women in 1987. Lung cancer is expected to account for 26% of all female cancer deaths in 2008. Table 3 provides the estimated number of cancer deaths in 2008 by state for selected cancer sites.


View this table:
[in this window]
[in a new window]

 
TABLE 3 Age-standardized Death Rates for All Cancers Combined, 2000 to 2004, and Estimated Deaths* from All Cancers Combined and Selected Sites by State, United States, 2008

 
    Regional Variations in Cancer Rates
Table 4 depicts cancer incidence for select cancer sites by state. For some sites, rates vary widely across states. For example, among the cancers listed in Table 4, the largest variations in the incidence rates, in proportionate terms, occurred in lung cancer in which rates (cases per 100,000 population) ranged from 40.3 in men and 20.9 in women in Utah to 137.9 in men and 74.9 in women in Kentucky. In contrast, the variation in female breast cancer incidence rates was small, ranging from 105.4 cases per 100,000 population in Mississippi to 142.2 cases in Washington. Factors that contribute to state variations in incidence rates include differences in the prevalence of risk factors, access to and utilization of early detection services, and completeness of reporting. For example, the state variation in lung cancer incidence rates primarily reflects differences in smoking prevalence. Utah ranks lowest in adult smoking prevalence and Kentucky highest.


View this table:
[in this window]
[in a new window]

 
TABLE 4 Cancer Incidence Rates* by Site and State, United States, 2000 to 2004

 
    Trends in Cancer Incidence and Mortality
Figures 2 to 5GoGoGo depict long-term trends in cancer incidence and death rates for all cancers combined and for selected cancer sites by sex. Table 5 shows incidence and mortality patterns for all cancer sites and for the 4 most common cancer sites based on joinpoint analysis. Trends in incidence were adjusted for delayed reporting. Delay-adjusted cancer incidence rates were stable in males from 1995 to 2004 and in females from 1999 to 2004. Death rates for all cancer sites combined decreased by 2.6% per year in males and by 1.8% in females from 2002 to 2004 compared with declines of 1.5% per year in males from 1992 to 2002 and 0.8% per year in females from 1994 to 2002.


Figure 2
View larger version (55K):
[in this window]
[in a new window]
[PowerPoint slide for Educational Purposes]
 
FIGURE 2 Annual Age-adjusted Cancer Incidence and Death Rates* for All Sites by Sex, United States, 1975 to 2004.

*Rates are age-adjusted to the 2000 US standard population. Incidence rates are adjusted for delays in reporting.

Source: Incidence—Surveillance, Epidemiology, and End Results (SEER) program, (www.seer.cancer.gov). Delay-Adjusted Incidence database: "SEER Incidence Delay-Adjusted Rates, 9 Registries, 1975–2004." National Cancer Institute, DCCPS, Surveillance Research Program, Statistical Research and Applications Branch, released April 2007, based on the November 2006 SEER data submission. Mortality—US Mortality Data, 1960 to 2004, National Center for Health Statistics, Centers for Disease Control and Prevention, 2006.

 

Figure 3
View larger version (78K):
[in this window]
[in a new window]
[PowerPoint slide for Educational Purposes]
 
FIGURE 3 Annual Age-adjusted Cancer Incidence Rates* for Selected Cancers by Sex, United States, 1975 to 2004.

*Rates are age-adjusted to the 2000 US standard population and adjusted for delays in reporting.

Source: Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov). Delay-Adjusted Incidence database: "SEER Incidence Delay-Adjusted Rates, 9 Registries, 1975–2004." National Cancer Institute, DCCPS, Surveillance Research Program, Statistical Research and Applications Branch, released April 2007, based on the November 2006 SEER data submission.

 

Figure 4
View larger version (64K):
[in this window]
[in a new window]
[PowerPoint slide for Educational Purposes]
 
FIGURE 4 Annual Age-adjusted Cancer Death Rates* Among Males for Selected Cancers, United States, 1930 to 2004.

*Rates are age-adjusted to the 2000 US standard population.

Note: Due to changes in ICD coding, numerator information has changed over time. Rates for cancers of the lung and bronchus, colon and rectum, and liver are affected by these changes.

Source: US Mortality Data, 1960 to 2004, US Mortality Volumes, 1930 to 1959, National Center for Health Statistics, Centers for Disease Control and Prevention, 2006.

 

Figure 5
View larger version (56K):
[in this window]
[in a new window]
[PowerPoint slide for Educational Purposes]
 
FIGURE 5 Annual Age-adjusted Cancer Death Rates* Among Females for Selected Cancers, United States, 1930 to 2004.

*Rates are age-adjusted to the 2000 US standard population.

{dagger}Uterus includes uterine cervix and uterine corpus.

Note: Due to changes in ICD coding, numerator information has changed over time. Rates for cancers of the uterus, ovary, lung and bronchus, and colon and rectum are affected by these changes.

Source: US Mortality Data, 1960 to 2004, US Mortality Volumes 1930 to 1959, National Center for Health Statistics, Centers for Disease Control and Prevention, 2006.

 

View this table:
[in this window]
[in a new window]

 
TABLE 5 Trends in Cancer Incidence and Death Rates for Selected Cancers by Sex, United States, 1975 to 2004

 
Mortality rates have continued to decrease across all 4 major cancer sites in both men and women, except for female lung cancer, in which rates continued to increase by 0.2% per year from 1995 to 2004 (Table 5). The incidence trends are mixed, however. Lung cancer incidence rates are declining in men and plateauing in women after increasing for many decades. The lag in the temporal trend of lung cancer incidence rates in women compared with men reflects historical differences in cigarette smoking between men and women; cigarette smoking in women peaked about 20 years later than in men. Colorectal cancer incidence rates have decreased from 1998 through 2004 in both males and females. Female breast cancer incidence rates decreased by 3.5% per year from 2001 to 2004 after increasing since 1980, likely reflecting both delays in diagnosis due to a decrease in mammography utilization and declines in hormone replacement therapy use among postmenopausal women.15–16 Prostate cancer incidence rates have stabilized from 1995 through 2004 following a short-term rapid increase and subsequent decrease between 1988 and 1995; these trends are thought to reflect changes in utilization of prostate-specific antigen testing.17–18

Table 6 shows the contribution of individual cancer sites to the total decrease in overall cancer death rates. Death rates from all cancers combined peaked in 1990 for men and in 1991 for women. Between 1990/1991 and 2004, death rates from cancer decreased by 18.4% among men and by 10.5% among women. Among men, reductions in death rates from lung, prostate, and colorectal cancers account for nearly 80% of the total decrease in cancer death rates, while reductions in death rates from breast and colorectal cancers account for 60% of the decrease among women. Lung cancer in men and breast cancer in women alone account for nearly 40% of the sex-specific decreases in cancer death rates. The decrease in lung cancer death rates among men is due to reduction in tobacco use over the past 40 years, while the decrease in death rates for colorectal, female breast, and prostate cancer largely reflects improvements in early detection and treatment.18 Between 1990/1991 and 2004, death rates increased substantially for lung cancer in women and for liver and intrahepatic bile duct cancer in men.


View this table:
[in this window]
[in a new window]

 
TABLE 6 The Contribution of Indvidual Cancer Sites to the Decrease in Cancer Death Rates, 1990 to 2004

 
    Recorded Number of Deaths from Cancer in 2005
A total of 559,312 cancer deaths were recorded in the United States in 2005, the most recent year for which actual data are available, accounting for about 23% of all deaths (Table 7). Despite a decrease in age-standardized death rates, there were 5,424 more cancer deaths reported in 2005 than in 2004 (3,592 in men and 1,832 in women) (Table 8). This contrasts with the decrease in the total number of cancer deaths that occurred from 2002 to 2003 and 2003 to 2004, in part due to a larger decrease in the age-standardized death rates from 2002 to 2004 (about 2% per year) compared with 2004 to 2005 (about 1% per year). With respect to the 4 major cancer sites, colorectal cancer death rates decreased by about 6% from 2003 to 2004 compared with only about 3% from 2004 to 2005. The declines in death rates for cancers of the lung and bronchus and prostate in men and breast in women were similarly attenuated from 2004 to 2005.


View this table:
[in this window]
[in a new window]

 
TABLE 7 Fifteen Leading Causes of Death, United States, 2005

 

View this table:
[in this window]
[in a new window]

 
Table 8 Trends in the Recorded Number of Deaths for Selected Cancers by Sex, United States, 1990 to 2005.

 
Cancer is one of the 5 leading causes of death in all age groups among both males and females (Table 9). Cancer is the leading cause of death among women aged 40 to 79 years and among men aged 60 to 79 years. Cancer is the leading cause of death among men and women under age 85 years (Figure 6). A total of 475,848 people under age 85 years died from cancer in the United States in 2005 compared with 408,550 deaths from heart disease.


View this table:
[in this window]
[in a new window]

 
Table 9 Ten Leading Causes of Death by Age and Sex, United States, 2005

 

Figure 6
View larger version (52K):
[in this window]
[in a new window]
[PowerPoint slide for Educational Purposes]
 
FIGURE 6 Death Rates* for Cancer and Heart Disease for Ages Younger than 85 and 85 and Older, 1975 to 2004.

*Rates are age-adjusted to the 2000 US standard population.

Source: US Mortality Data, 1960 to 2004, National Center for Health Statistics, Centers for Disease Control and Prevention, 2006.

 
Table 10 presents the number of deaths from the 5 most common cancer sites for males and females at various ages. Among males under age 40 years, leukemia is the most common fatal cancer, while cancer of the lung and bronchus predominates in men aged 40 years and older. Among females, leukemia is the leading cause of cancer death before age 20 years, breast cancer ranks first at age 20 to 59 years, and lung cancer ranks first at age 60 years and older.


View this table:
[in this window]
[in a new window]

 
Table 10 Reported Deaths for the Five Leading Cancer Sites by Age and Sex, United States, 2005

 
Figure 7 shows the total number of cancer deaths avoided since death rates began to decrease in 1991 in men and in 1992 in women. As a result, over a half million cancer deaths (408,400 in men and 136,100 in women) were averted during the time interval of 1991/1992 through 2004.


Figure 7
View larger version (47K):
[in this window]
[in a new window]
[PowerPoint slide for Educational Purposes]
 
FIGURE 7 Total Number of Cancer Deaths Avoided from 1991 to 2004 in Men and 1992 to 2004 in Women.

The blue line represents the actual number of cancer deaths recorded in each year, and the bold red line represents the expected number of cancer deaths if cancer mortality rates had remained the same since 1990/1991.

 
    CANCER OCCURRENCE BY RACE/ETHNICITY

Cancer incidence and death rates vary considerably among racial and ethnic groups (Table 11). For all cancer sites combined, African American men have a 19% higher incidence rate and a 37% higher death rate than White men, whereas African American women have a 6% lower incidence rate but a 17% higher death rate than White women. For the specific cancer sites listed in Table 11, incidence and death rates are consistently higher in African Americans than in Whites, except for cancers of the breast (incidence) and lung (incidence and mortality) among women and kidney (mortality) among both men and women. Factors known to contribute to racial disparities in mortality vary by cancer site and include differences in exposure to underlying risk factors (eg, historical smoking prevalence for lung cancer among men), access to high-quality regular screening (breast, cervical, and colorectal cancers), and timely diagnosis and treatment (for many cancers). The higher breast cancer incidence rates among Whites are thought to reflect a combination of factors that affect both diagnosis (such as more frequent mammography in White women) and the underlying factors that affect disease occurrence (such as later age at first birth and greater use of hormone replacement therapy among White compared with African American women).19


View this table:
[in this window]
[in a new window]

 
TABLE 11 Cancer Incidence and Death Rates* by Site, Race, and Ethnicity, United States, 2000 to 2004

 
Among other racial and ethnic groups, cancer incidence and death rates are lower than those in Whites and African Americans for all cancer sites combined and for the 4 most common cancer sites. However, incidence and death rates are generally higher in minority populations than in Whites for cancers of the uterine cervix, stomach, and liver. Stomach and liver cancer incidence and death rates are more than twice as high in Asian American/Pacific Islanders as in Whites, reflecting increased exposure to infectious agents such as Helicobacter pylori and hepatitis B and C.20 Kidney cancer mortality rates are the highest among American Indians/Alaska Natives, although obesity is the only factor known to contribute to this disparity.

Trends in cancer incidence can be adjusted for delayed reporting only in Whites and African Americans because long-term incidence data required for delay adjustment are not available for other racial and ethnic subgroups. From 1995 to 2004, incidence rates in males for all cancer sites combined (unadjusted for delayed reporting) decreased among all racial and ethnic groups except American Indian/Alaska Native men; among women, rates stabilized in all racial and ethnic groups during the same time period. In contrast, death rates from cancer significantly decreased in each racial and ethnic group, with larger decreases in men than in women.3

    Death Rates by Educational Attainment, Race, and Sex
Table 12 shows death rates for all cancers combined and the 4 major cancers by educational attainment among White and African American men and women aged 25 to 64 years in 2001.21 The death rate for all cancers combined among less-educated (≤12 years of education) compared with more-educated (>12 years of education) people was more than twice as high in men and about 40% higher in women. For specific cancer sites, the ratio of death rates in the less-educated compared with the more-educated group ranged from 1.16 for breast cancer among African American women to 3.36 for lung cancer among White men. For lung cancer in men and women and for colorectal cancer in men, the absolute difference in death rates between the less educated and more educated was larger than the difference between Whites and African Americans by sex at each level of educational attainment. Factors that contribute to higher death rates from cancer in less-educated men and women include higher prevalence of risk factors such as smoking and obesity and limited access to medical services.


View this table:
[in this window]
[in a new window]

 
TABLE 12 Cancer Death Rates* by Educational Attainment, Race, and Sex, United States, 2001

 
    Lifetime Probability of Developing Cancer
The lifetime probability of being diagnosed with an invasive cancer is higher for men (45%) than women (38%) (Table 13). However, because of the relatively early age of breast cancer onset, women have a slightly higher probability of developing cancer before age 60 years. It is noteworthy that these estimates are based on the average experience of the general population and may over- or underestimate individual risk because of differences in exposure and/or genetic susceptibility.


View this table:
[in this window]
[in a new window]

 
TABLE 13 Probability of Developing Invasive Cancers Within Selected Age Intervals by Sex, United States*

 
    Cancer Survival by Race
Compared with Whites, African American men and women have poorer survival once cancer is diagnosed. Five-year relative survival is lower in African Americans than in Whites within each stratum of stage of diagnosis for nearly every cancer site (Figure 8). These disparities may result from inequalities in access to and receipt of quality health care and/or from differences in comorbidities.18 As shown in Figure 9, African Americans are less likely than Whites to be diagnosed with cancer at a localized stage, when the disease may be more easily and successfully treated, and are more likely to be diagnosed with cancer at a regional or distant stage of disease. The extent to which factors other than stage at diagnosis contribute to the overall differential survival is unclear.22 However, some studies suggest that African Americans who receive cancer treatment and medical care similar to that of Whites experience similar outcomes.23


Figure 8
View larger version (156K):
[in this window]
[in a new window]
[PowerPoint slide for Educational Purposes]
 
FIGURE 8 Five-year Relative Survival Rates Among Patients Diagnosed with Selected Cancers by Race and Stage at Diagnosis, United States, 1996 to 2003.

* The rate for localized stage represents localized and regional stages combined.

{dagger}The standard error of the survival rate is between 5 and 10 percentage points.

Note: Staging according to Surveillance, Epidemiology, and End Results (SEER) historic stage categories rather than the American Joint Committee on Cancer (AJCC) staging system. Comparison of this data to that of previous years is discouraged due to the use of an expanded data set.

Source: Ries LAG, Melbert D, Krapcho M, et al.3

 

Figure 9
View larger version (127K):
[in this window]
[in a new window]
[PowerPoint slide for Educational Purposes]
 
FIGURE 9 Distribution of Selected Cancers by Race and Stage at Diagnosis, United States, 1996 to 2003.

*The rate for localized stage represents localized and regional stages combined.

Note: Staging according to Surveillance, Epidemiology, and End Results (SEER) historic stage categories rather than the American Joint Committee on Cancer (AJCC) staging system. For each cancer type, stage categories do not total 100% because sufficient information is not available to assign a stage to all cancer cases. Comparison of this data to that of previous years is discouraged due to the use of an expanded data set.

Source: Ries LAG, Melbert D, Krapcho M, et al.3

 
There have been notable improvements since 1975 in relative 5-year survival rates for many cancer sites and for all cancers combined (Table 14). This is true for both Whites and African Americans. Cancers for which survival has not improved substantially over the past 25 years include uterine corpus, cervix, larynx, lung, and pancreas. The improvement in survival reflects a combination of earlier diagnosis and improved treatments.


View this table:
[in this window]
[in a new window]

 
TABLE 14 Trends in 5-Year Relative Survival Rates* (%) by Race and Year of Diagnosis, United States, 1975 to 2003

 
Relative survival rates cannot be calculated for racial and ethnic populations other than Whites and African Americans because accurate life expectancies (the average number of years of life remaining for persons who have attained a given age) are not available. However, based on cause-specific survival rates of cancer patients diagnosed from 1992 to 2000 in SEER areas of the United States, all minority populations except Asian American/Pacific Islander women have a greater probability of dying from cancer within 5 years of diagnosis than non-Hispanic Whites, after accounting for differences in stage at diagnosis.18,24 For the 4 major cancer sites (prostate, female breast, lung and bronchus, and colon and rectum), minority populations are more likely to be diagnosed at distant stage compared with non-Hispanic Whites.24

    CANCER IN CHILDREN

Cancer is the second most common cause of death among children between the age of 1 and 14 years in the United States, surpassed only by accidents (Table 15). Leukemia (particularly acute lymphocytic leukemia) is the most common cancer in children (aged 0 to 14 years), followed by cancer of the brain and other nervous system, neuroblastoma, renal (Wilms) tumors, and non-Hodgkin lymphoma.3 Over the past 25 years, there have been significant improvements in the 5-year relative survival rate for all of the major childhood cancers (Table 16). The 5-year relative survival rate among children for all cancer sites combined improved from 58% for patients diagnosed in 1975 to 1977 to 80% for those diagnosed in 1996 to 2003.3


View this table:
[in this window]
[in a new window]

 
Table 15 Fifteen leading Causes of Death Among Children Aged 1 to 14, United states, 2005

 

View this table:
[in this window]
[in a new window]

 
TABLE 16 Trends in Five-year Relative Survival Rates* (%) for Children Under Age 15, United States, 1975 to 2003

 
    LIMITATIONS

Estimates of the expected numbers of new cancer cases and cancer deaths should be interpreted cautiously. These estimates may vary considerably from year to year, particularly for less common cancers and in states with smaller populations. Estimates are also affected by changes in method. The introduction of a new method for projecting incident cancer cases beginning with the 2007 estimates substantially affected the estimates for a number of cancers, particularly leukemia and female breast (see Pickle et al12 for more detailed discussion). Not all changes in cancer trends are captured by modeling techniques. For these reasons, we discourage the use of these estimates to track year-to-year changes in cancer occurrence and death. The preferred data sources for tracking cancer trends are the age-standardized or age-specific cancer death rates from the NCHS and cancer incidence rates from SEER or NPCR, even though these data are 3 and 4 years old, respectively, by the time that they become available. Nevertheless, the American Cancer Society estimates of the number of new cancer cases and deaths in the current year provide reasonably accurate estimates of the burden of new cancer cases and deaths in the United States.

    Footnotes

Published online through CA First Look at http://CAonline.AmCancerSoc.org.

* Disclaimer: The findings and conclusions in this report are those of the author and do not necessarily represent the views of the Centers for Disease Control and Prevention. Back

    REFERENCES

  1. National Center for Health Statistics, Division of Vital Statistics, Centers for Disease Control and Prevention. Available at: http://www.cdc.gov/nchs/nvss.htm. Accessed November 15, 2007.
  2. National Cancer Institute, US National Institutes of Health. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence—SEER 9 Regs Public-Use, Nov 2006 Sub (1973–2004), Linked to County Attributes, Total US, 1969–2004 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2007, based on the November 2006 submission.
  3. Ries LAG, Melbert D, Krapcho M, et al. SEER Cancer Statistics Review, 1975–2004. National Cancer Institute: Bethesda, MD. http://seer.cancer.gov/csr/1975_2004/, based on November 2006 SEER data submission, posted to the SEER Web site, 2007.
  4. National Cancer Institute, US National Institutes of Health. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence—SEER 13 Regs Public-Use, Nov 2006 Sub (1992–2004), Linked to County Attributes, Total US, 1969–2004 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2007, based on the November 2006 submission.
  5. National Cancer Institute, US National Institutes of Health. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence—SEER 17 Regs Public-Use, Nov 2006 Sub (2000–2004), Linked to County Attributes, Total US, 1969–2004 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2007, based on the November 2006 submission.
  6. Wu XC, McLaughlin CC, Lake A, et al. Cancer in North America, 2000–2004. Volume One: Incidence. Springfield, IL: North American Association of Central Cancer Registries, Inc.; 2007.
  7. US Census Bureau. Available at: http://www.census.gov. Accessed September 16, 2007.
  8. Manual of the International Statistical Classification of Diseases, Injuries, and Causes of Death. Vol. 1, 10th revision. Geneva, Switzerland: World Health Organization; 1992.
  9. Manual of the International Statistical Classification of Diseases, Injuries, and Causes of Death. Vol. 1, 9th revision. Geneva, Switzerland: World Health Organization; 1975.
  10. Manual of the International Statistical Classification of Diseases, Injuries, and Causes of Death. Vol. 1, 8th revision. Geneva, Switzerland: World Health Organization; 1967.
  11. Fritz A, Percy C, Jack A, et al. International Classification of Diseases for Oncology, 3rd ed. Geneva, Switzerland: World Health Organization; 2000.
  12. Pickle LW, Hao Y, Jemal A, et al. A new method of estimating United States and state-level cancer incidence counts for the current calendar year. CA Cancer J Clin 2007;57:30–42.[Abstract/Free Full Text]
  13. Tiwari RC, Ghosh K, Jemal A, et al. A new method of predicting US and state-level cancer mortality counts for the current calendar year. CA Cancer J Clin 2004;54:30–40.[Abstract/Free Full Text]
  14. Clegg LX, Feuer EJ, Midthune DN, et al. Impact of reporting delay and reporting error on cancer incidence rates and trends. J Natl Cancer Inst 2002;94:1537–1545.[Abstract/Free Full Text]
  15. Jemal A, Ward E, Thun MJ. Recent trends in breast cancer incidence rates by age and tumor characteristics among U.S. women. Breast Cancer Res 2007;9:R28.[CrossRef][Medline]
  16. Ravdin PM, Cronin KA, Howlader N, et al. The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med 2007;356:1670–1674.[Abstract/Free Full Text]
  17. Espey DK, Wu XC, Swan J, et al. Annual report to the nation on the status of cancer, 1975–2004, featuring cancer in American Indians and Alaska Natives. Cancer 2007;110:2119–2152.[CrossRef][Medline]
  18. Jemal A, Clegg LX, Ward E, et al. Annual report to the nation on the status of cancer, 1975–2001, with a special feature regarding survival. Cancer 2004;101:3–27.[CrossRef][Medline]
  19. Ghafoor A, Jemal A, Ward E, et al. Trends in breast cancer by race and ethnicity. CA Cancer J Clin 2003;53:342–355.[Abstract/Free Full Text]
  20. Ward E, Jemal A, Cokkinides V, et al. Cancer disparities by race/ethnicity and socioeconomic status. CA Cancer J Clin 2004;54:78–93.[Abstract/Free Full Text]
  21. Albano JD, Ward E, Jemal A, et al. Cancer mortality in the United States by education level and race. J Natl Cancer Inst 2007;99:1384–1394.[Abstract/Free Full Text]
  22. Ghafoor A, Jemal A, Cokkinides V, et al. Cancer statistics for African Americans. CA Cancer J Clin 2002;52:326–341.[Abstract/Free Full Text]
  23. Bach PB, Schrag D, Brawley OW, et al. Survival of blacks and whites after a cancer diagnosis. JAMA 2002;287:2106–2113.[Abstract/Free Full Text]
  24. Clegg LX, Li FP, Hankey BF, et al. Cancer survival among US whites and minorities: a SEER (Surveillance, Epidemiology, and End Results) Program population-based study. Arch Intern Med 2002;162:1985–1993.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
Am J Clin PatholHome page
E. Montgomery
Refining Diagnostic Criteria for High-Grade Dysplasia in Barrett Esophagus
Am J Clin Pathol, July 1, 2009; 132(1): 7 - 9.
[Full Text] [PDF]


Home page
Eur Respir JHome page
I. Horvath, Z. Lazar, N. Gyulai, M. Kollai, and G. Losonczy
Exhaled biomarkers in lung cancer
Eur. Respir. J., July 1, 2009; 34(1): 261 - 275.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
R. Chugh, J. K. Wathen, R. G. Maki, R. S. Benjamin, S. R. Patel, P. A. Myers, D. A. Priebat, D. K. Reinke, D. G. Thomas, M. L. Keohan, et al.
Phase II Multicenter Trial of Imatinib in 10 Histologic Subtypes of Sarcoma Using a Bayesian Hierarchical Statistical Model
J. Clin. Oncol., July 1, 2009; 27(19): 3148 - 3153.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
T. Andre, C. Boni, M. Navarro, J. Tabernero, T. Hickish, C. Topham, A. Bonetti, P. Clingan, J. Bridgewater, F. Rivera, et al.
Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial
J. Clin. Oncol., July 1, 2009; 27(19): 3109 - 3116.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
I. Zighelboim, A. P. Schmidt, F. Gao, P. H. Thaker, M. A. Powell, J. S. Rader, R. K. Gibb, D. G. Mutch, and P. J. Goodfellow
ATR Mutation in Endometrioid Endometrial Cancer Is Associated With Poor Clinical Outcomes
J. Clin. Oncol., July 1, 2009; 27(19): 3091 - 3096.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Roentgenol.Home page
C. H. McCollough, L. Guimaraes, and J. G. Fletcher
In Defense of Body CT
Am. J. Roentgenol., July 1, 2009; 193(1): 28 - 39.
[Abstract] [Full Text] [PDF]


Home page
RadiologyHome page
T. Franiel, L. Ludemann, B. Rudolph, H. Rehbein, C. Stephan, M. Taupitz, and D. Beyersdorff
Prostate MR Imaging: Tissue Characterization with Pharmacokinetic Volume and Blood Flow Parameters and Correlation with Histologic Parameters
Radiology, July 1, 2009; 252(1): 101 - 108.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
N. Kemeny, M. Capanu, M. D'Angelica, W. Jarnagin, D. Haviland, R. Dematteo, and Y. Fong
Phase I trial of adjuvant hepatic arterial infusion (HAI) with floxuridine (FUDR) and dexamethasone plus systemic oxaliplatin, 5-fluorouracil and leucovorin in patients with resected liver metastases from colorectal cancer
Ann. Onc., July 1, 2009; 20(7): 1236 - 1241.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
S. Papineni, S. Chintharlapalli, M. Abdelrahim, S.-o. Lee, R. Burghardt, A. Abudayyeh, C. Baker, L. Herrera, and S. Safe
Tolfenamic acid inhibits esophageal cancer through repression of specificity proteins and c-Met
Carcinogenesis, July 1, 2009; 30(7): 1193 - 1201.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
C. Yan, B. Shieh, P. Reigan, Z. Zhang, M. A. Colucci, A. Chilloux, J. J. Newsome, D. Siegel, D. Chan, C. J. Moody, et al.
Potent Activity of Indolequinones against Human Pancreatic Cancer: Identification of Thioredoxin Reductase as a Potential Target
Mol. Pharmacol., July 1, 2009; 76(1): 163 - 172.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S. Banerjee, Z. Wang, D. Kong, and F. H. Sarkar
3,3'-Diindolylmethane Enhances Chemosensitivity of Multiple Chemotherapeutic Agents in Pancreatic Cancer
Cancer Res., July 1, 2009; 69(13): 5592 - 5600.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
S. Takaishi, S. Tu, Z. A. Dubeykovskaya, M. T. Whary, S. Muthupalani, B. H. Rickman, A. B. Rogers, N. Lertkowit, A. Varro, J. G. Fox, et al.
Gastrin Is an Essential Cofactor for Helicobacter-Associated Gastric Corpus Carcinogenesis in C57BL/6 Mice
Am. J. Pathol., July 1, 2009; 175(1): 365 - 375.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
C.-W. Chua, Y.-T. Chiu, H.-F. Yuen, K.-W. Chan, K. Man, X. Wang, M.-T. Ling, and Y.-C. Wong
Suppression of Androgen-Independent Prostate Cancer Cell Aggressiveness by FTY720: Validating Runx2 as a Potential Antimetastatic Drug Screening Platform
Clin. Cancer Res., July 1, 2009; 15(13): 4322 - 4335.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
S. Morita, I. Okamoto, K. Kobayashi, K. Yamazaki, H. Asahina, A. Inoue, K. Hagiwara, N. Sunaga, N. Yanagitani, T. Hida, et al.
Combined Survival Analysis of Prospective Clinical Trials of Gefitinib for Non-Small Cell Lung Cancer with EGFR Mutations
Clin. Cancer Res., July 1, 2009; 15(13): 4493 - 4498.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
E. Finlayson
Computed Tomographic Colonography for Patients at High Risk of Colorectal Cancer: Trading Accuracy for Access and Compliance
JAMA, June 17, 2009; 301(23): 2498 - 2499.
[Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
M. R. Cooperberg, J. M. Broering, and P. R. Carroll
Risk Assessment for Prostate Cancer Metastasis and Mortality at the Time of Diagnosis
J Natl Cancer Inst, June 16, 2009; 101(12): 878 - 887.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
A. M. Al-Katib, A. Aboukameel, R. Mohammad, M.-C. Bissery, and C. Zuany-Amorim
Superior Antitumor Activity of SAR3419 to Rituximab in Xenograft Models for Non-Hodgkin's Lymphoma
Clin. Cancer Res., June 15, 2009; 15(12): 4038 - 4045.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
N.V. Rajeshkumar, A. C. Tan, E. De Oliveira, C. Womack, H. Wombwell, S. Morgan, M. V. Warren, J. Walker, T. P. Green, A. Jimeno, et al.
Antitumor Effects and Biomarkers of Activity of AZD0530, a Src Inhibitor, in Pancreatic Cancer
Clin. Cancer Res., June 15, 2009; 15(12): 4138 - 4146.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
S. Halabi, N. J. Vogelzang, S.-S. Ou, K. Owzar, L. Archer, and E. J. Small
Progression-Free Survival as a Predictor of Overall Survival in Men With Castrate-Resistant Prostate Cancer
J. Clin. Oncol., June 10, 2009; 27(17): 2766 - 2771.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
G. P. Kim, D. J. Sargent, M. R. Mahoney, K. M. Rowland Jr, P. A. Philip, E. Mitchell, A. P. Mathews, T. R. Fitch, R. M. Goldberg, S. R. Alberts, et al.
Phase III Noninferiority Trial Comparing Irinotecan With Oxaliplatin, Fluorouracil, and Leucovorin in Patients With Advanced Colorectal Carcinoma Previously Treated With Fluorouracil: N9841
J. Clin. Oncol., June 10, 2009; 27(17): 2848 - 2854.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
D. K. Chang, A. L. Johns, N. D. Merrett, A. J. Gill, E. K. Colvin, C. J. Scarlett, N. Q. Nguyen, R. W.L. Leong, P. H. Cosman, M. I. Kelly, et al.
Margin Clearance and Outcome in Resected Pancreatic Cancer
J. Clin. Oncol., June 10, 2009; 27(17): 2855 - 2862.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
B. D. Smith, G. L. Smith, A. Hurria, G. N. Hortobagyi, and T. A. Buchholz
Future of Cancer Incidence in the United States: Burdens Upon an Aging, Changing Nation
J. Clin. Oncol., June 10, 2009; 27(17): 2758 - 2765.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
V. Lakshmikanthan, L. Zou, J. I. Kim, A. Michal, Z. Nie, N. C. Messias, J. L. Benovic, and Y. Daaka
Identification of {beta}Arrestin2 as a corepressor of androgen receptor signaling in prostate cancer
PNAS, June 9, 2009; 106(23): 9379 - 9384.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
A. Umar and P. Greenwald
Alarming Colorectal Cancer Incidence Trends: A Case for Early Detection and Prevention
Cancer Epidemiol. Biomarkers Prev., June 1, 2009; 18(6): 1672 - 1673.
[Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
M. M. Center, A. Jemal, and E. Ward
International Trends in Colorectal Cancer Incidence Rates
Cancer Epidemiol. Biomarkers Prev., June 1, 2009; 18(6): 1688 - 1694.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
A. L. Van Dyke, M. L. Cote, A. S. Wenzlaff, W. Chen, J. Abrams, S. Land, C. N. Giroux, and A. G. Schwartz
Cytokine and Cytokine Receptor Single-Nucleotide Polymorphisms Predict Risk for Non-Small Cell Lung Cancer among Women
Cancer Epidemiol. Biomarkers Prev., June 1, 2009; 18(6): 1829 - 1840.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
S. H. Golden, K. A. Robinson, I. Saldanha, B. Anton, and P. W. Ladenson
Prevalence and Incidence of Endocrine and Metabolic Disorders in the United States: A Comprehensive Review
J. Clin. Endocrinol. Metab., June 1, 2009; 94(6): 1853 - 1878.
[Abstract] [Full Text] [PDF]


Home page
INT J SURG PATHOLHome page
S. Simonetti, R. Russo, G. Ciancia, V. Altieri, G. De Rosa, and L. Insabato
Role of Polysomy 17 in Transitional Cell Carcinoma of the Bladder: Immunohistochemical Study of HER2/neu Expression and FISH Analysis of c-erbB-2 Gene and Chromosome 17
International Journal of Surgical Pathology, June 1, 2009; 17(3): 198 - 205.
[Abstract] [PDF]


Home page
Endocr Relat CancerHome page
J. M D'Antonio, D. J Vander Griend, and J. T Isaacs
DNA licensing as a novel androgen receptor mediated therapeutic target for prostate cancer
Endocr. Relat. Cancer, June 1, 2009; 16(2): 325 - 332.
[Abstract] [Full Text] [PDF]


Home page
Endocr Relat CancerHome page
M. Bagnoli, F. Ambrogi, S. Pilotti, P. Alberti, A. Ditto, M. Barbareschi, E. Galligioni, E. Biganzoli, S. Canevari, and D. Mezzanzanica
c-FLIPL expression defines two ovarian cancer patient subsets and is a prognostic factor of adverse outcome
Endocr. Relat. Cancer, June 1, 2009; 16(2): 443 - 453.
[Abstract] [Full Text] [PDF]


Home page
Jpn J Clin OncolHome page
N.-P. Tang, B. Zhou, B. Wang, R.-B. Yu, and J. Ma
Flavonoids Intake and Risk of Lung Cancer: A Meta-analysis
Jpn. J. Clin. Oncol., June 1, 2009; 39(6): 352 - 359.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
C. L. Costantino, A. K. Witkiewicz, Y. Kuwano, J. A. Cozzitorto, E. P. Kennedy, A. Dasgupta, J. C. Keen, C. J. Yeo, M. Gorospe, and J. R. Brody
The Role of HuR in Gemcitabine Efficacy in Pancreatic Cancer: HuR Up-regulates the Expression of the Gemcitabine Metabolizing Enzyme Deoxycytidine Kinase
Cancer Res., June 1, 2009; 69(11): 4567 - 4572.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
M. J. Overman, G. R. Varadhachary, S. Kopetz, R. Adinin, E. Lin, J. S. Morris, C. Eng, J. L. Abbruzzese, and R. A. Wolff
Phase II Study of Capecitabine and Oxaliplatin for Advanced Adenocarcinoma of the Small Bowel and Ampulla of Vater
J. Clin. Oncol., June 1, 2009; 27(16): 2598 - 2603.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
A.R.M. R. Amin, O. Kucuk, F. R. Khuri, and D. M. Shin
Perspectives for Cancer Prevention With Natural Compounds
J. Clin. Oncol., June 1, 2009; 27(16): 2712 - 2725.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
A. A. Chen, C. J. Marsit, B. C. Christensen, E.A. Houseman, M. D. McClean, J. F. Smith, J. T. Bryan, M. R. Posner, H. H. Nelson, and K. T. Kelsey
Genetic variation in the vitamin C transporter, SLC23A2, modifies the risk of HPV16-associated head and neck cancer
Carcinogenesis, June 1, 2009; 30(6): 977 - 981.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
M. E. Zafereo, E. M. Sturgis, Z. Liu, L.-E Wang, Q. Wei, and G. Li
Nucleotide excision repair core gene polymorphisms and risk of second primary malignancy in patients with index squamous cell carcinoma of the head and neck
Carcinogenesis, June 1, 2009; 30(6): 997 - 1002.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Roentgenol.Home page
G. J. Kelloff, P. Choyke, D. S. Coffey, and for The Prostate Cancer Imaging Working Group
Challenges in Clinical Prostate Cancer: Role of Imaging
Am. J. Roentgenol., June 1, 2009; 192(6): 1455 - 1470.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Roentgenol.Home page
R. H. Cohan, E. M. Caoili, N. C. Cowan, A. Z. Weizer, and J. H. Ellis
MDCT Urography: Exploring a New Paradigm for Imaging of Bladder Cancer
Am. J. Roentgenol., June 1, 2009; 192(6): 1501 - 1508.
[Abstract] [Full Text] [PDF]


Home page
Anticancer ResHome page
C. M. MACH, L. MATHEW, S. A. MOSLEY, R. KURZROCK, and J. A. SMITH
Determination of Minimum Effective Dose and Optimal Dosing Schedule for Liposomal Curcumin in a Xenograft Human Pancreatic Cancer Model
Anticancer Res, June 1, 2009; 29(6): 1895 - 1899.
[Abstract] [Full Text] [PDF]


Home page
Anticancer ResHome page
A. CHHABRA, A. VERMA, and K. MEHTA
Tissue Transglutaminase Promotes or Suppresses Tumors Depending on Cell Context
Anticancer Res, June 1, 2009; 29(6): 1909 - 1919.
[Abstract] [Full Text] [PDF]


Home page
Anticancer ResHome page
S. D. RICE, J. E. BUSH, and S. L. BROWER
Assessment of Erlotinib in Chemoresponse Assay
Anticancer Res, June 1, 2009; 29(6): 1993 - 1997.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
A. DiFeo, F. Huang, J. Sangodkar, E. A. Terzo, D. Leake, G. Narla, and J. A. Martignetti
KLF6-SV1 Is a Novel Antiapoptotic Protein That Targets the BH3-Only Protein NOXA for Degradation and Whose Inhibition Extends Survival in an Ovarian Cancer Model
Cancer Res., June 1, 2009; 69(11): 4733 - 4741.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
D. C. Tomlinson, F. R. Lamont, S. D. Shnyder, and M. A. Knowles
Fibroblast Growth Factor Receptor 1 Promotes Proliferation and Survival via Activation of the Mitogen-Activated Protein Kinase Pathway in Bladder Cancer
Cancer Res., June 1, 2009; 69(11): 4613 - 4620.
[Abstract] [Full Text] [PDF]


Home page
Cancer Prevention ResearchHome page
A.R.M. R. Amin, F. R. Khuri, Z. Chen, and D. M. Shin
Synergistic Growth Inhibition of Squamous Cell Carcinoma of the Head and Neck by Erlotinib and Epigallocatechin-3-Gallate: The Role of p53-Dependent Inhibition of Nuclear Factor-{kappa}B
Cancer Prevention Research, June 1, 2009; 2(6): 538 - 545.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
R. N. Donahue, P. J. McLaughlin, and I. S. Zagon
Cell proliferation of human ovarian cancer is regulated by the opioid growth factor-opioid growth factor receptor axis
Am J Physiol Regulatory Integrative Comp Physiol, June 1, 2009; 296(6): R1716 - R1725.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
D. R. Soto-Pantoja, J. Menon, P. E. Gallagher, and E. A. Tallant
Angiotensin-(1-7) inhibits tumor angiogenesis in human lung cancer xenografts with a reduction in vascular endothelial growth factor
Mol. Cancer Ther., June 1, 2009; 8(6): 1676 - 1683.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
S. Sundaram, C. Durairaj, R. Kadam, and U. B. Kompella
Luteinizing hormone-releasing hormone receptor-targeted deslorelin-docetaxel conjugate enhances efficacy of docetaxel in prostate cancer therapy
Mol. Cancer Ther., June 1, 2009; 8(6): 1655 - 1665.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
H. Li, D. Wang, H. Zhang, K. Kirmani, Z. Zhao, R. Steinmetz, and Y. Xu
Lysophosphatidic acid stimulates cell migration, invasion, and colony formation as well as tumorigenesis/metastasis of mouse ovarian cancer in immunocompetent mice
Mol. Cancer Ther., June 1, 2009; 8(6): 1692 - 1701.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
I. Abiatari, T. DeOliveira, V. Kerkadze, C. Schwager, I. Esposito, N. A. Giese, P. Huber, F. Bergman, A. Abdollahi, H. Friess, et al.
Consensus transcriptome signature of perineural invasion in pancreatic carcinoma
Mol. Cancer Ther., June 1, 2009; 8(6): 1494 - 1504.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
R. Hildenbrand, M. Niedergethmann, A. Marx, D. Belharazem, H. Allgayer, C. Schleger, and P. Strobel
Amplification of the Urokinase-Type Plasminogen Activator Receptor (uPAR) Gene in Ductal Pancreatic Carcinomas Identifies a Clinically High-Risk Group
Am. J. Pathol., June 1, 2009; 174(6): 2246 - 2253.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
P. Brader, K. J. Kelly, N. Chen, Y. A. Yu, Q. Zhang, P. Zanzonico, E. M. Burnazi, R. E. Ghani, I. Serganova, H. Hricak, et al.
Imaging a Genetically Engineered Oncolytic Vaccinia Virus (GLV-1h99) Using a Human Norepinephrine Transporter Reporter Gene
Clin. Cancer Res., June 1, 2009; 15(11): 3791 - 3801.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
N. Ballian, D. M. Mahvi, and G. D. Kennedy
Colonoscopic Findings and Tumor Site Do Not Predict Bowel Obstruction During Medical Treatment of Stage IV Colorectal Cancer
Oncologist, June 1, 2009; 14(6): 580 - 585.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
B. M. Weiss, J. Abadie, P. Verma, R. S. Howard, and W. M. Kuehl
A monoclonal gammopathy precedes multiple myeloma in most patients
Blood, May 28, 2009; 113(22): 5418 - 5422.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
M. G. Sanda and I. D. Kaplan
A 64-Year-Old Man With Low-Risk Prostate Cancer: Review of Prostate Cancer Treatment
JAMA, May 27, 2009; 301(20): 2141 - 2151.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
P. N. Lara Jr, R. Natale, J. Crowley, H. J. Lenz, M. W. Redman, J. E. Carleton, J. Jett, C. J. Langer, J. P. Kuebler, S. R. Dakhil, et al.
Phase III Trial of Irinotecan/Cisplatin Compared With Etoposide/Cisplatin in Extensive-Stage Small-Cell Lung Cancer: Clinical and Pharmacogenomic Results From SWOG S0124
J. Clin. Oncol., May 20, 2009; 27(15): 2530 - 2535.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
G. Mountzios, M. A. Dimopoulos, A. Bamias, G. Vourli, H. Kalofonos, G. Aravantinos, G. Fountzilas, and C. A. Papadimitriou
Randomized multicenter phase II trial of cisplatin and ifosfamide with or without paclitaxel in recurrent or metastatic carcinoma of the uterine cervix: a Hellenic Cooperative Oncology Group (HeCOG) study
Ann. Onc., May 20, 2009; (2009) mdn797v1.
[Abstract] [Full Text] [PDF]


Home page
Hum Mol GenetHome page
J. L. Stanford, L. M. FitzGerald, S. K. McDonnell, E. E. Carlson, L. M. McIntosh, K. Deutsch, L. Hood, E. A. Ostrander, and D. J. Schaid
Dense genome-wide SNP linkage scan in 301 hereditary prostate cancer families identifies multiple regions with suggestive evidence for linkage
Hum. Mol. Genet., May 15, 2009; 18(10): 1839 - 1848.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
H. K. Roy, V. Turzhitsky, Y. Kim, M. J. Goldberg, P. Watson, J. D. Rogers, A. J. Gomes, A. Kromine, R. E. Brand, M. Jameel, et al.
Association between Rectal Optical Signatures and Colonic Neoplasia: Potential Applications for Screening
Cancer Res., May 15, 2009; 69(10): 4476 - 4483.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
A. R. Raimondi, A. Molinolo, and J. S. Gutkind
Rapamycin Prevents Early Onset of Tumorigenesis in an Oral-Specific K-ras and p53 Two-Hit Carcinogenesis Model
Cancer Res., May 15, 2009; 69(10): 4159 - 4166.
[Abstract] [Full Text] [PDF]


Home page
Am J EpidemiolHome page
M. M. Heinen, B. A. J. Verhage, T. A. W. Ambergen, R. A. Goldbohm, and P. A. van den Brandt
Alcohol Consumption and Risk of Pancreatic Cancer in the Netherlands Cohort Study
Am. J. Epidemiol., May 15, 2009; 169(10): 1233 - 1242.
[Abstract] [Full Text] [PDF]


Home page
Am J EpidemiolHome page
J. E. Lee, S. E. Hankinson, and E. Cho
Reproductive Factors and Risk of Renal Cell Cancer: The Nurses' Health Study
Am. J. Epidemiol., May 15, 2009; 169(10): 1243 - 1250.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
J. A. Dubovsky, D. G. McNeel, J. J. Powers, J. Gordon, E. M. Sotomayor, and J. A. Pinilla-Ibarz
Treatment of Chronic Lymphocytic Leukemia with a Hypomethylating Agent Induces Expression of NXF2, an Immunogenic Cancer Testis Antigen
Clin. Cancer Res., May 15, 2009; 15(10): 3406 - 3415.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
O. B. Rickman, P. K. Vohra, B. Sanyal, J. A. Vrana, M.-C. Aubry, D. A. Wigle, and C. F. Thomas Jr.
Analysis of ErbB Receptors in Pulmonary Carcinoid Tumors
Clin. Cancer Res., May 15, 2009; 15(10): 3315 - 3324.
[Abstract] [Full Text] [PDF]


Home page
ANN INTERN MEDHome page
E. P. Gelmann and S. M. Henshall
Clinically Relevant Prognostic Markers for Prostate Cancer: The Search Goes On
Ann Intern Med, May 5, 2009; 150(9): 647 - 649.
[Full Text] [PDF]


Home page
Am J Clin PatholHome page
R. T. Vollmer
Differential Diagnosis in Immunohistochemistry With Bayes Theorem
Am J Clin Pathol, May 1, 2009; 131(5): 723 - 730.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
J. A. Satia, A. Littman, C. G. Slatore, J. A. Galanko, and E. White
Associations of Herbal and Specialty Supplements with Lung and Colorectal Cancer Risk in the VITamins And Lifestyle Study
Cancer Epidemiol. Biomarkers Prev., May 1, 2009; 18(5): 1419 - 1428.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
S. Rohrmann, C. G. Sutcliffe, J. L. Bienstock, D. Monsegue, F. Akereyeni, G. Bradwin, N. Rifai, M. N. Pollak, T. Agurs-Collins, and E. A. Platz
Racial Variation in Sex Steroid Hormones and the Insulin-Like Growth Factor Axis in Umbilical Cord Blood of Male Neonates
Cancer Epidemiol. Biomarkers Prev., May 1, 2009; 18(5): 1484 - 1491.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
E. Sidelnikov, R. M. Bostick, W. D. Flanders, Q. Long, V. L. Cohen, C. Dash, M. E. Seabrook, and V. Fedirko
MutL-Homolog 1 Expression and Risk of Incident, Sporadic Colorectal Adenoma: Search for Prospective Biomarkers of Risk for Colorectal Cancer
Cancer Epidemiol. Biomarkers Prev., May 1, 2009; 18(5): 1599 - 1609.
[Abstract] [Full Text] [PDF]


Home page
In VivoHome page
E.A. KOTTEAS, A. ADAMOPOULOS, P.D. DROGITIS, A. ZALONIS, K.V. GIANNOPOULOS, E.M. KARAPANAGIOTOU, M. W. SAIF, and K.N. SYRIGOS
Gastrointestinal Bleeding as Initial Presentation of Melanoma of Unknown Primary Origin: Report of a Case and Review of the Literature
In Vivo, May 1, 2009; 23(3): 487 - 489.
[Abstract] [Full Text] [PDF]


Home page
J Mol EndocrinolHome page
M. Eisold, M. Asim, H. Eskelinen, T. Linke, and A. Baniahmad
Inhibition of MAPK-signaling pathway promotes the interaction of the corepressor SMRT with the human androgen receptor and mediates repression of prostate cancer cell growth in the presence of antiandrogens
J. Mol. Endocrinol., May 1, 2009; 42(5): 429 - 435.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
M. Chen, J. Ni, H.-C. Chang, C.-Y. Lin, M. Muyan, and S. Yeh
CCDC62/ERAP75 functions as a coactivator to enhance estrogen receptor beta-mediated transactivation and target gene expression in prostate cancer cells
Carcinogenesis, May 1, 2009; 30(5): 841 - 850.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
M. R. Posner, C. M. Norris, L. J. Wirth, D. M. Shin, K. J. Cullen, E. W. Winquist, C. R. Blajman, E. A. Mickiewicz, G. P. Frenette, L. F. Plinar, et al.
Sequential therapy for the locally advanced larynx and hypopharynx cancer subgroup in TAX 324: survival, surgery, and organ preservation
Ann. Onc., May 1, 2009; 20(5): 921 - 927.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
F. Lovat, A. Bitto, S.-Q. Xu, M. Fassan, S. Goldoni, D. Metalli, V. Wubah, P. McCue, G. Serrero, L. G. Gomella, et al.
Proepithelin is an autocrine growth factor for bladder cancer
Carcinogenesis, May 1, 2009; 30(5): 861 - 868.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
J. Pan, J. Lin, J. G. Izzo, Y. Liu, J. Xing, M. Huang, J. A. Ajani, and X. Wu
Genetic susceptibility to esophageal cancer: the role of the nucleotide excision repair pathway
Carcinogenesis, May 1, 2009; 30(5): 785 - 792.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
H. Hu, J. Zhang, H. J. Lee, S.-H. Kim, and J. Lu
Penta-O-galloyl-beta-D-glucose induces S- and G1-cell cycle arrests in prostate cancer cells targeting DNA replication and cyclin D1
Carcinogenesis, May 1, 2009; 30(5): 818 - 823.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
M. Dror Michaelson, M. M. Regan, W. K. Oh, D. S. Kaufman, K. Olivier, S. Z. Michaelson, B. Spicer, C. Gurski, P. W. Kantoff, and M. R. Smith
Phase II study of sunitinib in men with advanced prostate cancer
Ann. Onc., May 1, 2009; 20(5): 913 - 920.
[Abstract] [Full Text] [PDF]


Home page
Stem CellsHome page
S. Takaishi, T. Okumura, S. Tu, S. S.W. Wang, W. Shibata, R. Vigneshwaran, S. A.K. Gordon, Y. Shimada, and T. C. Wang
Identification of Gastric Cancer Stem Cells Using the Cell Surface Marker CD44
Stem Cells, May 1, 2009; 27(5): 1006 - 1020.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
K.-T. Kuo, B. Guan, Y. Feng, T.-L. Mao, X. Chen, N. Jinawath, Y. Wang, R. J. Kurman, I.-M. Shih, and T.-L. Wang
Analysis of DNA Copy Number Alterations in Ovarian Serous Tumors Identifies New Molecular Genetic Changes in Low-Grade and High-Grade Carcinomas
Cancer Res., May 1, 2009; 69(9): 4036 - 4042.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
R. Wang, D. S. Morris, S. A. Tomlins, R. J. Lonigro, A. Tsodikov, R. Mehra, T. J. Giordano, L. P. Kunju, C. T. Lee, A. Z. Weizer, et al.
Development of a Multiplex Quantitative PCR Signature to Predict Progression in Non-Muscle-Invasive Bladder Cancer
Cancer Res., May 1, 2009; 69(9): 3810 - 3818.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
J. L. Watters, M. H. Gail, S. J. Weinstein, J. Virtamo, and D. Albanes
Associations between {alpha}-Tocopherol, {beta}-Carotene, and Retinol and Prostate Cancer Survival
Cancer Res., May 1, 2009; 69(9): 3833 - 3841.
[Abstract] [Full Text] [PDF]


Home page
Anticancer ResHome page
Z. MORISE, A. SUGIOKA, Y. TANAHASHI, Y. OKABE, M. IKEDA, T. KAGAWA, and C. TAKEURA
Treatment of Patients with Unresectable Advanced Carcinoma of Biliary Tract - Chemotherapy and Surgical Resection
Anticancer Res, May 1, 2009; 29(5): 1783 - 1786.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Gastrointest. Liver Physiol.Home page
D. Y. Lim and J. H. Y. Park
Induction of p53 contributes to apoptosis of HCT-116 human colon cancer cells induced by the dietary compound fisetin
Am J Physiol Gastrointest Liver Physiol, May 1, 2009; 296(5): G1060 - G1068.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
L.-F. de Geus-Oei, D. Vriens, H. W.M. van Laarhoven, W. T.A. van der Graaf, and W. J.G. Oyen
Monitoring and Predicting Response to Therapy with 18F-FDG PET in Colorectal Cancer: A Systematic Review
J. Nucl. Med., May 1, 2009; 50(Suppl_1): 43S - 54S.
[Abstract] [Full Text] [PDF]


Home page
Cancer Prevention ResearchHome page
K. Kelly, J. Kittelson, W. A. Franklin, T. C. Kennedy, C. E. Klein, R. L. Keith, E. C. Dempsey, M. Lewis, M. K. Jackson, F. R. Hirsch, et al.
A Randomized Phase II Chemoprevention Trial of 13-CIS Retinoic Acid with Or without {alpha} Tocopherol or Observation in Subjects at High Risk for Lung Cancer
Cancer Prevention Research, May 1, 2009; 2(5): 440 - 449.
[Abstract] [Full Text] [PDF]


Home page
Cancer Prevention ResearchHome page
L. Wang, M. J.L. Bonorden, G.-x. Li, H.-J. Lee, H. Hu, Y. Zhang, J. D. Liao, M. P. Cleary, and J. Lu
Methyl-Selenium Compounds Inhibit Prostate Carcinogenesis in the Transgenic Adenocarcinoma of Mouse Prostate Model with Survival Benefit
Cancer Prevention Research, May 1, 2009; 2(5): 484 - 495.
[Abstract] [Full Text] [PDF]


Home page
Cancer Prevention ResearchHome page
L. Vitale-Cross, R. Czerninski, P. Amornphimoltham, V. Patel, A. A. Molinolo, and J. S. Gutkind
Chemical Carcinogenesis Models for Evaluating Molecular-Targeted Prevention and Treatment of Oral Cancer
Cancer Prevention Research, May 1, 2009; 2(5): 419 - 422.
[Full Text] [PDF]


Home page
Cancer Prevention ResearchHome page
G. J. Kelloff, C. C. Sigman, and C. H. Contag
Early Detection of Oral Neoplasia: Watching with New Eyes
Cancer Prevention Research, May 1, 2009; 2(5): 405 - 408.
[Full Text] [PDF]


Home page
J. Nutr.Home page
Y. Su, K. Shankar, and R. C. M. Simmen
Early Soy Exposure via Maternal Diet Regulates Rat Mammary Epithelial Differentiation by Paracrine Signaling from Stromal Adipocytes
J. Nutr., May 1, 2009; 139(5): 945 - 951.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
D. G. Power and N. E. Kemeny
The role of floxuridine in metastatic liver disease
Mol. Cancer Ther., May 1, 2009; 8(5): 1015 - 1025.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
G. Lurje, P. C. Manegold, Y. Ning, A. Pohl, W. Zhang, and H.-J. Lenz
Thymidylate synthase gene variations: predictive and prognostic markers
Mol. Cancer Ther., May 1, 2009; 8(5): 1000 - 1007.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
L. Moretti, K. W. Kim, D. K. Jung, C. D. Willey, and B. Lu
Radiosensitization of solid tumors by Z-VAD, a pan-caspase inhibitor
Mol. Cancer Ther., May 1, 2009; 8(5): 1270 - 1279.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
D. J. Vander Griend, L. Antony, S. L. Dalrymple, Y. Xu, S. B. Christensen, S. R. Denmeade, and J. T. Isaacs
Amino acid containing thapsigargin analogues deplete androgen receptor protein via synthesis inhibition and induce the death of prostate cancer cells
Mol. Cancer Ther., May 1, 2009; 8(5): 1340 - 1349.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
D. Z. Qian, C.-Y. Huang, C. A. O'Brien, I. M. Coleman, M. Garzotto, L. D. True, C. S. Higano, R. Vessella, P. H. Lange, P. S. Nelson, et al.
Prostate Cancer-Associated Gene Expression Alterations Determined from Needle Biopsies
Clin. Cancer Res., May 1, 2009; 15(9): 3135 - 3142.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
S. T. Huyn, J. B. Burton, M. Sato, M. Carey, S. S. Gambhir, and L. Wu
A Potent, Imaging Adenoviral Vector Driven by the Cancer-selective Mucin-1 Promoter That Targets Breast Cancer Metastasis
Clin. Cancer Res., May 1, 2009; 15(9): 3126 - 3134.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
G. Liu, W. K. Kelly, G. Wilding, L. Leopold, K. Brill, and B. Somer
An Open-Label, Multicenter, Phase I/II Study of Single-Agent AT-101 in Men with Castrate-Resistant Prostate Cancer
Clin. Cancer Res., May 1, 2009; 15(9): 3172 - 3176.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow All Versions of this Article:
CA.2007.0010v1
58/2/71    most recent
Right arrow Submit a letter to the editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jemal, A.
Right arrow Articles by Thun, M. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jemal, A.
Right arrow Articles by Thun, M. J.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVECOVER ARCHIVE SEARCH